サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1655298

マイコプラズマ検査の世界市場

Mycoplasma Testing

出版日
ページ情報
英文 158 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
マイコプラズマ検査の世界市場
出版日: 2025年02月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 158 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

マイコプラズマ検査の世界市場は2030年までに19億米ドルに達する見込み

2024年に11億米ドルと推定されたマイコプラズマ検査の世界市場は、2030年には19億米ドルに達し、分析期間2024-2030年のCAGRは8.6%で成長すると予測されます。マイコプラズマ検査アッセイ、キット、試薬は、本レポートで分析したセグメントの1つであり、分析期間終了までにCAGR 9.4％を記録し、9億4,080万米ドルに達すると予測されます。マイコプラズマ検査サービス分野の成長率は、分析期間中CAGR 8.1％と推定されます。

米国市場は2億9,190万米ドルと推定、中国はCAGR 12.7％で成長予測

米国のマイコプラズマ検査市場は、2024年に2億9,190万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを12.7%として、2030年までに4億8,320万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.4%と7.7%と予測されています。欧州では、ドイツがCAGR 5.4%で成長すると予測されています。

世界のマイコプラズマ検査市場動向と促進要因まとめ

マイコプラズマ検査とは何か、なぜバイオ医薬品と細胞培養に不可欠なのか？

マイコプラズマ検査とは、細胞培養、バイオ医薬品、ワクチンにおけるマイコプラズマ汚染の検出を指します。マイコプラズマは細胞壁を持たない細菌の一群であり、バイオ医薬品の製造に使用される細胞培養において汚染を引き起こす可能性があります。その小ささと柔軟性により、従来のフィルターを通過し、検出されることなくバイオテクノロジーのプロセスを汚染し、製品の安全性と有効性を損ないます。マイコプラズマの汚染は、細胞生理学の変化、不正確な実験結果、製品の回収につながる可能性があるため、研究所、製薬企業、バイオ医薬品製造施設では日常的な検査が不可欠です。マイコプラズマの検査は、規制基準を確実に遵守し、医療や研究に使用される細胞由来製品の完全性を維持するために不可欠です。

技術の進歩はマイコプラズマの検査法をどのように形成しているか？

技術革新は、マイコプラズマ検査の精度、スピード、信頼性を著しく向上させています。伝統的に、マイコプラズマの検出は培養に基づく方法で行われており、これは時間と労力がかかり、結果が出るまでに数週間を要します。しかし、ポリメラーゼ連鎖反応（PCR）やリアルタイムPCR（qPCR）のような分子診断学の進歩は、より迅速、高感度、特異的な汚染検出を可能にし、マイコプラズマ検査に革命をもたらしました。さらに、核酸増幅技術（NAATs）や次世代シークエンシング（NGS）技術は、検出能力をさらに向上させ、より広範なマイコプラズマ種の同定を可能にしています。自動化された検査プラットフォームは、ルーチン検査に必要な時間と労力を削減し、検査室や生産施設がリアルタイムで汚染のない環境を確保することを容易にしています。

規制要件と業界標準は、マイコプラズマ検査の需要にどのような影響を与えていますか？

バイオ医薬品製造における厳しい規制要件と、安全で効果的なバイオテクノロジー製品への需要の高まりが、マイコプラズマ検査の需要を促進しています。米国食品医薬品局（FDA）や欧州医薬品庁（EMA）のような規制機関は、製品の安全性を確保し、汚染を防ぐために、細胞ベースの製品、生物製剤、ワクチンに日常的なマイコプラズマ検査を義務付けています。これらの規制を遵守することは、製薬会社が製品承認を維持し、費用のかかる遅延やリコールを回避するために不可欠です。バイオ医薬品業界の成長と、CRO（医薬品開発業務受託機関）やCMO（医薬品製造業務受託機関）の拡大も、より迅速で信頼性の高い調査方法の採用を後押ししています。さらに、汚染リスクが製品の生存率に大きな影響を及ぼす可能性のある細胞治療や遺伝子治療の増加に伴い、厳格な試験プロトコルの必要性がさらに高まっています。

マイコプラズマ検査市場の主な成長促進要因は？

マイコプラズマ検査市場の成長は、分子診断学の進歩、規制当局の監視強化、バイオ医薬品生産の拡大など、いくつかの要因によってもたらされます。PCRやNGSのような、より迅速で精密な検査法へのシフトは、汚染検出を強化し、これらの技術を業界でますます普及させています。生物製剤、ワクチン、細胞ベースの治療法の普及が進んでいることも、これらの製品が特に汚染の影響を受けやすいことから、信頼性の高いマイコプラズマ検査に対する需要の拡大に寄与しています。さらに、生物製剤や細胞培養の定期的な検査を義務付ける規制要件が、高度なマイコプラズマ検出ソリューションの採用をさらに後押ししています。製薬業界では、コンプライアンスと製品の安全性を確保するために強固な検査プロトコルが要求されるため、受託研究・製造サービスの利用が増加していることも促進要因となっています。最後に、バイオテクノロジープロセスにおける品質管理への関心の高まりは、より効率的で自動化された検査プラットフォームの継続的な開発を促進し、市場の成長をさらに加速させています。

セグメント

提供（アッセイ、キット＆試薬、サービス、機器）;手法（核酸検査（NAT）、ELISA、染色、その他の手法）;アプリケーション（細胞株検査、生産終了細胞検査、ウイルス検査、その他のアプリケーション）

調査対象企業の例（注目の11社）

  • American Type Culture Collection（ATCC）
  • Biological Industries Israel Beit Haemek Ltd.
  • Biounique Testing Laboratories Inc.
  • Charles River Laboratories International, Inc.
  • Invivogen
  • Lonza Group AG
  • Merck KgaA
  • Norgen Biotek Corporation
  • Promocell GmbH
  • Roche Diagnostics（Schweiz）AG
  • SGS SA
  • Thermo Fisher Scientific, Inc.
  • Wuxi Apptec Co., Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP13520

Global Mycoplasma Testing Market to Reach US$1.9 Billion by 2030

The global market for Mycoplasma Testing estimated at US$1.1 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 8.6% over the analysis period 2024-2030. Mycoplasma Testing Assays, Kits & Reagents, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$940.8 Million by the end of the analysis period. Growth in the Mycoplasma Testing Services segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$291.9 Million While China is Forecast to Grow at 12.7% CAGR

The Mycoplasma Testing market in the U.S. is estimated at US$291.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$483.2 Million by the year 2030 trailing a CAGR of 12.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Global Mycoplasma Testing Market – Key Trends & Drivers Summarized

What Is Mycoplasma Testing and Why Is It Essential in Biopharmaceuticals and Cell Cultures?

Mycoplasma testing refers to the detection of mycoplasma contamination in cell cultures, biopharmaceutical products, and vaccines. Mycoplasmas are a group of bacteria that lack a cell wall and can cause contamination in cell cultures used in biopharmaceutical production. Due to their small size and flexibility, they can pass through conventional filters and contaminate biotechnological processes without detection, compromising product safety and efficacy. Mycoplasma contamination can lead to alterations in cell physiology, inaccurate experimental results, and product recalls, making routine testing essential in laboratories, pharmaceutical companies, and biopharmaceutical production facilities. Testing for mycoplasma is critical for ensuring compliance with regulatory standards and maintaining the integrity of cell-based products used in medical treatments and research.

How Are Technological Advances Shaping Mycoplasma Testing Methods?

Technological innovations are significantly improving the accuracy, speed, and reliability of mycoplasma testing. Traditionally, mycoplasma detection was performed using culture-based methods, which are time-consuming and labor-intensive, taking weeks to yield results. However, advancements in molecular diagnostics, such as polymerase chain reaction (PCR) and real-time PCR (qPCR), have revolutionized mycoplasma testing by enabling faster, more sensitive, and specific detection of contamination. Additionally, nucleic acid amplification techniques (NAATs) and next-generation sequencing (NGS) technologies are further enhancing detection capabilities, allowing for the identification of a broader range of mycoplasma species. Automated testing platforms are also reducing the time and labor required for routine testing, making it easier for laboratories and production facilities to ensure contamination-free environments in real-time.

How Are Regulatory Requirements and Industry Standards Impacting the Demand for Mycoplasma Testing?

Stringent regulatory requirements in biopharmaceutical production and the increasing demand for safe and effective biotechnological products are driving the demand for mycoplasma testing. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) mandate routine mycoplasma testing for cell-based products, biologics, and vaccines to ensure product safety and prevent contamination. Compliance with these regulations is critical for pharmaceutical companies to maintain product approval and avoid costly delays or recalls. The growing biopharmaceutical industry, along with the expansion of contract research organizations (CROs) and contract manufacturing organizations (CMOs), is also pushing the adoption of faster and more reliable mycoplasma testing methods. Moreover, with the rise in cell and gene therapies, where contamination risks can significantly affect product viability, the need for stringent testing protocols has become even more essential.

What Are the Key Growth Drivers in the Mycoplasma Testing Market?

The growth in the mycoplasma testing market is driven by several factors, including advancements in molecular diagnostics, increased regulatory scrutiny, and the expansion of biopharmaceutical production. The shift toward faster and more precise testing methods, such as PCR and NGS, is enhancing contamination detection, making these technologies increasingly popular in the industry. The rising prevalence of biologics, vaccines, and cell-based therapies is also contributing to the growing demand for reliable mycoplasma testing, as these products are particularly susceptible to contamination. Additionally, regulatory requirements mandating regular testing of biologics and cell cultures are further pushing the adoption of advanced mycoplasma detection solutions. The growing use of contract research and manufacturing services in the pharmaceutical industry is another driver, as these organizations require robust testing protocols to ensure compliance and product safety. Lastly, the increasing focus on quality control in biotechnological processes is promoting the continuous development of more efficient and automated testing platforms, further accelerating market growth.

SCOPE OF STUDY:

The report analyzes the Mycoplasma Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Assays, Kits & Reagents, Services, Instruments); Technique (Nucleic Acid Testing (NAT), ELISA, Staining, Other Techniques); Application (Cell Line Testing, End-of-Production Cell Testing, Virus Testing, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 11 Featured) -

  • American Type Culture Collection (ATCC)
  • Biological Industries Israel Beit Haemek Ltd.
  • Biounique Testing Laboratories Inc.
  • Charles River Laboratories International, Inc.
  • Invivogen
  • Lonza Group AG
  • Merck KgaA
  • Norgen Biotek Corporation
  • Promocell GmbH
  • Roche Diagnostics (Schweiz) AG
  • SGS SA
  • Thermo Fisher Scientific, Inc.
  • Wuxi Apptec Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Mycoplasma Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Adoption of Biopharmaceuticals Spurs Demand for Mycoplasma Testing in Manufacturing
    • Increasing Regulatory Scrutiny Expands Addressable Market for Mycoplasma Testing in Drug Development
    • Technological Advancements in PCR-Based Testing Strengthen Business Case for Rapid Mycoplasma Detection
    • Growth in Cell Culture-Based Research Drives Adoption of Routine Mycoplasma Testing in Laboratories
    • Increasing Use of Mycoplasma Testing in Gene and Cell Therapies Expands Market for Advanced Testing Solutions
    • Rising Focus on Contamination Control in Biomanufacturing Propels Growth in Mycoplasma Testing Services
    • Expansion of Contract Research Organizations (CROs) Fuels Demand for Outsourced Mycoplasma Testing
    • Increasing Investment in Vaccine Development Strengthens Market for Mycoplasma Testing in Biopharma R&D
    • Expansion of Stem Cell Research and Regenerative Medicine Spurs Demand for Mycoplasma Testing in Cell Cultures
    • Technological Innovations in Digital PCR Propel Growth in Sensitivity and Speed of Mycoplasma Detection
    • Rising Demand for Mycoplasma-Free Biological Products Drives Adoption of Testing Protocols in Drug Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mycoplasma Testing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mycoplasma Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mycoplasma Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Mycoplasma Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Assays, Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Assays, Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Assays, Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Nucleic Acid Testing (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Nucleic Acid Testing (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Nucleic Acid Testing (NAT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for ELISA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Staining by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Staining by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Staining by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Techniques by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cell Line Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cell Line Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Cell Line Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for End-of-Production Cell Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for End-of-Production Cell Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for End-of-Production Cell Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Virus Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Virus Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Virus Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Mycoplasma Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Mycoplasma Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Mycoplasma Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Mycoplasma Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Mycoplasma Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Mycoplasma Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • INDIA
    • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Mycoplasma Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Mycoplasma Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Mycoplasma Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Mycoplasma Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Mycoplasma Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Mycoplasma Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Mycoplasma Testing by Offering - Assays, Kits & Reagents, Services and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Mycoplasma Testing by Offering - Percentage Breakdown of Value Sales for Assays, Kits & Reagents, Services and Instruments for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Mycoplasma Testing by Technique - Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Mycoplasma Testing by Technique - Percentage Breakdown of Value Sales for Nucleic Acid Testing (NAT), ELISA, Staining and Other Techniques for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Mycoplasma Testing by Application - Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Mycoplasma Testing by Application - Percentage Breakdown of Value Sales for Cell Line Testing, End-of-Production Cell Testing, Virus Testing and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION